[HTML][HTML] Immunotherapy: boosting efficacy and overcoming resistance
E IO, ESH CLL - memoinoncology.com
The global, randomized, open-label, phase III POSEIDON trial evaluated the PD-L1 inhibitor
durvalumab with or without the anti-CTLA-4 antibody tremelimumab in addition to …
durvalumab with or without the anti-CTLA-4 antibody tremelimumab in addition to …